Auriga Laboratories, Inc. Watch

from 8-K 6 pages Amended and Restated Senior Secured Convertible Promissory Note Due February 12, 2009

from 8-K 4 pages Amendment No. 1 to Security Agreement

from 8-K 10 pages Auriga Laboratories, Inc. Senior Secured Convertible Promissory Note Purchase Agreement

from 8-K 4 pages Royalty Participation Agreement

from 8-K 6 pages Senior Secured Convertible Promissory Note Due June 8, 2009

from 10KSB 5 pages License Agreement Between Outlook Pharmaceuticals, Inc. and Auriga Laboratories, Inc. Confidential License Agreement

from 10KSB 5 pages Co-Promotion Agreement

from 8-K 3 pages Royalty Participation Agreement

from 8-K 9 pages Auriga Laboratories, Inc. Senior Secured Note and Warrant Purchase Agreement

from 8-K 3 pages Auriga Laboratories, Inc. Common Stock Warrant

from 8-K 2 pages Security Agreement

from 8-K 5 pages Senior Secured Promissory Note Due February 12, 2009

from 8-K ~5 pages Secured & Collateralized Promissory Note $1,800,000 Plus Interest Due & Payable Document C-01152008

from 8-K ~10 pages Convertible Promissory Note $1,800,000 Plus Interest Due & Payable Document B-01152008

from 8-K 4 pages Convertible Promissory Note $240,000 Plus Interest Due & Payable Document A-01152008

from 8-K 6 pages On December 12, 2007 (The "Transaction Date"), Malibu Pharma, Inc. ("Acquiree") Entered Into a Purchase Agreement (The "Purchase Agreement") With Auriga Laboratories, Inc. (The "Company") Pursuant to Which Acquiree Acquired All Right, Title and Interest in 100% of the Issued and Outstanding Membership Units (The "Units") of Stesso ("Stesso") in Exchange for a Promissory Note From Acquiree in Favor of the Company (The "Note") of Even Date Therewith (The "Transaction"). It Has Come to the Acquiree's Attention That the Company Wishes to Rescind the Transaction. Malibu Is Willing to Rescind the Transaction by Returning the Units to Auriga in Exchange for a Return to Malibu of the Note and the Mutual Covenants Contained Herein (The "Rescission"). Now, Therefore, in Consideration of the Mutual Agreements Herein, the Receipt and Sufficiency of Which Is Hereby Acknowledged, and in Light of the Recitals Stated Herein, the Parties Hereto Agree as Follows

from 8-K 7 pages Standard Office Lease by and Between Camarillo Office Partners I, LLC, a California Limited Liability Company, as Landlord, and Auriga Laboratories, Inc., a Delaware Corporation, as Tenant Suite 150 5284 Adolfo Road, Camarillo, California

from 8-K 2 pages Registration Rights Agreement

from 8-K 9 pages Investment Agreement

from 8-K 21 pages Agreement